PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 280.14% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 280.14% | -- | |||
| Cost of Revenue | 258.55% | -- | |||
| Gross Profit | 322.47% | -- | |||
| SG&A Expenses | 114.30% | 196.84% | |||
| Depreciation & Amortization | 239.02% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 148.45% | 290.64% | |||
| Operating Income | -84.98% | -163.63% | |||
| Income Before Tax | -64.91% | -189.15% | |||
| Income Tax Expenses | 400.00% | -- | |||
| Earnings from Continuing Operations | -65.09% | -189.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 208.33% | -- | |||
| Net Income | -64.33% | -189.88% | |||
| EBIT | -84.98% | -163.63% | |||
| EBITDA | -79.95% | -- | |||
| EPS Basic | 19.23% | -5.41% | |||
| Normalized Basic EPS | 20.41% | -6.52% | |||
| EPS Diluted | 19.23% | -5.41% | |||
| Normalized Diluted EPS | 20.41% | -6.52% | |||
| Average Basic Shares Outstanding | 103.37% | 174.39% | |||
| Average Diluted Shares Outstanding | 103.37% | 174.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||